SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry
Currently, a second dramatic upsurge of SARS-CoV-2 infection rates is observed across Europe, and there is an urgent need to clarify the imminent risk for our melanoma patients under immune checkpoint inhibition (ICI). To this aim, we reviewed the clinical course of disease for all patients included in the registry of the German working group of dermato-oncology (ADOreg, www.hautkrebsregister.de) database with confirmed SARS-CoV-2 infection.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Rose K.C. Moritz, Ralf Gutzmer, Lisa Zimmer, Friedegund Meier, Misbah S. Ahmed, Sabine Sell, Max Schlaak, Florian Kapp, Michael M. Sachse, Sebastian Haferkamp, Julia Welzel, Katharina C. K ähler, Michael Weichenthal Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Dermatology | Germany Health | Melanoma | SARS | Skin Cancer